



## Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy

10/03/22

CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that it will present three posters at the upcoming 29<sup>th</sup> Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), taking place October 11-14, 2022, in Edinburgh, Scotland.

### Poster Presentation Details:

**Presentation Title:** Identification of a Cell Surface Receptor Utilized by an Engineered BBB-Penetrant Capsid Family with Enhanced Brain Tropism in Non-Human Primates and Mice

**Poster Number:** P024

**Presenting Author:** Brett Hoffman, Ph.D., Senior Scientist, Capsid Discovery

**Presentation Title:** Dose-Response Evaluation of 9P801, an Engineered AAV Capsid with High BBB Penetration and CNS Transduction in Non-Human Primates

**Poster Number:** P015

**Presenting Author:** Mathieu Nonnenmacher, Ph.D., Vice President, Capsid Discovery

**Presentation Title:** Evaluation of an Early, Late, Very Late Expressed Rep in a Recombinant Baculovirus to Produce a More Potent AAV-based Gene Therapeutic in Insect Cells

**Poster Number:** P065

**Presenting Author:** Jeffrey Slack, Ph.D., Principal Scientist, Cell Culture Development

### About Voyager Therapeutics

Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the modality to treat devastating diseases. Proprietary capsids born from the Company's TRACER discovery platform are powering a rich early-stage pipeline of programs and may elevate the field to overcome the narrow therapeutic window associated with conventional gene therapy vectors across neurologic disorders and other therapeutic areas. [voyagertherapeutics.com](http://voyagertherapeutics.com) [LinkedIn](#) [Twitter](#)

Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

### Contacts

Investors

[investors@vygr.com](mailto:investors@vygr.com)

### Media

Peg Rusconi

[prusconi@vergescientific.com](mailto:prusconi@vergescientific.com)



Source: Voyager Therapeutics, Inc.